School of Life Science & Technology, China Pharmaceutical University, Nanjing 210009, PR China.
Biotechnol Prog. 2009 Nov-Dec;25(6):1703-8. doi: 10.1002/btpr.252.
Vascular endothelial growth factor receptor-2 (VEGFR-2) plays an important role in stimulating the proliferation of endothelial cells and improving the permeability of blood vessels, which is involved in tumor angiogenesis, a process that is essential for tumor growth and metastasis. In this study, we describe a method for high yield of recombinant extracellular domain 3 (KDR3) of human VEGFR-2 in an Escherichia coli system with further purification by cation exchange chromatography and immobilized metal affinity chromatography (IMAC). The biological activity of recombinant KDR3 was performed by sequestering VEGF in HUVEC proliferation assay. The real-time binding of human VEGF to immobilized KDR3 was monitored by a label-free biosensor, Optical waveguide lightmode spectroscopy (OWLS). Under the given experimental conditions, the association rate constant k(a) was 4.2 x 10(3) M(-1) s(-1) and the dissociation rate k(d) was 5.1 x 10(-3) s(-1). The dissociation constant K(D) was then calculated to be 1.2 x 10(-6) M. The obtained values will serve as baseline parameters for the design of improved versions of recombinant soluble VEGF receptors and the evaluation of developed anti-KDR antibodies. In addition, such a scenario established by the use of OWLS will potentiate the kinetic study of ligand/receptor and antigen/antibody. The receptor discussed here, which block VEGF binding to cell membrane KDR, have potential clinical application in the treatment of cancer and other diseases where pathological angiogenesis is involved.
血管内皮生长因子受体-2(VEGFR-2)在刺激内皮细胞增殖和提高血管通透性方面发挥着重要作用,参与肿瘤血管生成,这是肿瘤生长和转移所必需的过程。在本研究中,我们描述了一种在大肠杆菌系统中高效表达人 VEGFR-2 胞外结构域 3(KDR3)的方法,并通过阳离子交换层析和固定化金属亲和层析(IMAC)进一步纯化。通过在 HUVEC 增殖测定中隔离 VEGF 来测定重组 KDR3 的生物学活性。通过无标记生物传感器光学波导光模光谱(OWLS)监测人 VEGF 与固定化 KDR3 的实时结合。在给定的实验条件下,缔合速率常数 k(a)为 4.2 x 10(3) M(-1) s(-1),解离速率常数 k(d)为 5.1 x 10(-3) s(-1)。然后计算出解离常数 K(D)为 1.2 x 10(-6) M。获得的值将作为设计改良型重组可溶性 VEGF 受体和评估开发的抗 KDR 抗体的基础参数。此外,OWLS 建立的这种方案将增强配体/受体和抗原/抗体的动力学研究。这里讨论的受体可以阻断 VEGF 与细胞膜 KDR 的结合,在治疗癌症和其他涉及病理性血管生成的疾病方面具有潜在的临床应用。